Evidence map›Paper›PMID 25091672›Full record

ReviewVaccine2014

Insights from global data for use of rotavirus vaccines in India.

T S Rao, Rashmi Arora, Ajay Khera, Jacqueline E Tate, Umesh Parashar, Gagandeep Kang, Indian Rotavirus Vaccine Working Group

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

T S RaoDepartment of Biotechnology, Ministry of Science and Technology, Government of India, CGO Complex, New Delhi, India.
Rashmi AroraDivision of Epidemiology and Communicable Diseases, Indian Council for Medical Research, Ansari Nagar, New Delhi, India.
Ajay KheraChild Health and Immunization, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi, India.
Jacqueline E TateViral Gastroenteritis Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Umesh ParasharViral Gastroenteritis Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Gagandeep KangDivision of Gastrointestinal Sciences, Christian Medical College, Vellore 632004, Tamil Nadu, India. Electronic address: gkang@cmcvellore.ac.in.
Indian Rotavirus Vaccine Working Group

Funding

Intramural CDC HHS CC999999Wellcome Trust
6 · The paper itself

Abstract

Rotavirus vaccines are being introduced in several low- and middle-income countries across the world with and without support from the GAVI Alliance. India has the highest disease burden of rotavirus based on morbidity and mortality estimates and several indigenous vaccine manufacturers are developing rotavirus vaccines. One candidate has undergone phase III testing and others have completed evaluation in phase II. Global data on licensed vaccine performance in terms of impact on disease, strain diversity, safety and cost-effectiveness has been reviewed to provide a framework for decision making in India.

Indexed as

Child, PreschoolCost-Benefit AnalysisCost of IllnessDecision MakingHumansImmunization ProgramsIndiaInfantRotavirusRotavirus InfectionsRotavirus VaccinesRotavirus Vaccines

Identifiers

PMID25091672
PMCPMC12011198

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.